Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference
December 07 2017 - 5:30AM
Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene
therapy company developing treatments for rare inherited retinal
diseases, today announced that the company will participate in a
fireside chat at the BMO Capital Markets Prescriptions for Success
Healthcare Conference on Thursday, Dec. 14, 2017 at 9:00 a.m. ET in
New York City.
To access the live webcast, please visit
ir.nightstartx.com. A replay of the webcast will be available on
the Nightstar website for 60 days following the conference.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company
focused on developing and commercializing novel one-time treatments
for patients suffering from rare inherited retinal diseases that
would otherwise progress to blindness. Nightstar’s lead product
candidate, NSR-REP1, is being developed as a treatment for patients
with choroideremia, a rare, degenerative, genetic retinal disorder
that has no current treatments and affects approximately one in
every 50,000 people. Positive results from a Phase 1/2 trial of
NSR-REP1 were published in The Lancet in 2014 and in The New
England Journal of Medicine in 2016. Nightstar plans to commence a
Phase 3 registrational trial of NSR-REP1 for choroideremia at sites
in the United States, Europe and Canada in the first half of 2018.
Nightstar’s second product candidate, NSR-RPGR, is currently being
evaluated in a Phase 1/2 clinical trial for the treatment of
patients with X-linked retinitis pigmentosa, an inherited X-linked
recessive retinal disease that affects approximately one in every
40,000 people.
For more information about Nightstar or its clinical trials,
please visit www.nightstartx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to: statements about our plans to
develop and commercialize our product candidates, our planned
clinical trials for NSR-REP1 and NSR-RPGR, the clinical utility of
our product candidates, the prevalence of patient populations for
our targeted indications, and the utility of prior preclinical and
clinical data in determining future clinical results . These
forward-looking statements are based on management's current
expectations of future events and are subject to a number of
involve substantial known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of
activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking
statements, including the risks and uncertainties set forth in the
"Risk Factors" section of our prospectus filed pursuant to Rule
424(b)(4) under the U.S. Securities Act of 1933, as amended, on
September 28, 2017, and subsequent reports that we file with the
U.S. Securities and Exchange Commission. We may not actually
achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements we make. The
forward-looking statements in this press release represent our
views as of the date hereof. We anticipate that subsequent events
and developments will cause our views to change. However, while we
may elect to update these forward-looking statements at some point
in the future, we have no current intention of doing so except to
the extent required by applicable law. You should, therefore, not
rely on these forward-looking statements as representing our views
as of any date subsequent to the date of this press release.
Contact:
Senthil Sundaram, Chief Financial
Officerinvestors@nightstartx.com
Alicia Davis, THRUST IR910-620-3302alicia@thrustir.com
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jul 2023 to Jul 2024